Skip to main content
NCBI home page
The Yale Journal of Biology and Medicine logoLink to The Yale Journal of Biology and Medicine
. 1992 Sep-Oct;65(5):505–536.

The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.

L K Kvols 1, J C Reubi 1, U Horisberger 1, C G Moertel 1, J Rubin 1, J W Charboneau 1
PMCID: PMC2589749  PMID: 1364090

Abstract

In 77 percent of patients suffering from a malignant carcinoid syndrome, administration of the somatostatin analog, octreotide (SMS 201-995, Sandostatin) induced clinical improvement coupled with a decrease in 24-hour urinary 5-hydroxyindole acetic acid (5-HIAA). This finding prompted an evaluation to determine the correlation between the presence of somatostatin receptors in tumor tissue and the response to octreotide in patients with advanced, metastatic, neuroendocrine tumors. In tissues of 31 tumors (20 carcinoid, eight islet-cell carcinoma, three medullary thyroid carcinomas), the presence of somatostatin receptors was analyzed by binding of the somatostatin analog 125I-Tyr3-SMS 201-995 and autoradiography. Receptors were detected in 16 of 20 samples of carcinoid tissues; all but one patient with receptor-positive tumors improved clinically after treatment with octreotide, and the urine 5-HIAA level was reduced a median of 63 percent (range, 39-94 percent) compared to values before treatment. Of the receptor-negative carcinoid patients, only one showed clinical improvement, which was minimal, and there was a negligible reduction in 5-HIAA after octreotide therapy. All eight patients with metastatic islet-cell carcinomas were positive for somatostatin receptors. Symptomatic improvement and a > 50 percent decrease in the level of at least one of the pathologically elevated marker hormones was seen in all eight. None of the three patients with medullary carcinoma of the thyroid had a decrease in calcitonin, and all three were initially somatostatin receptor-negative. We conclude that the presence of somatostatin receptors in malignant neuroendocrine tumor tissue appears to correlate with the response to octreotide therapy. Analysis of somatostatin receptors in malignant neuroendocrine carcinoma tissue should be included in future prospective clinical trials of this synthetic peptide.

Full text

PDF
505

Images in this article

513FIG. 4
on p.513
513FIG. 5
on p.513
514FIG. 6
on p.514
514FIG. 7
on p.514
515FIG. 8
on p.515
515FIG. 9
on p.515

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Kvols L. K., Buck M., Moertel C. G., Schutt A. J., Rubin J., O'Connell M. J., Hahn R. G. Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995). Ann Intern Med. 1987 Aug;107(2):162–168. doi: 10.7326/0003-4819-107-2-162. [DOI] [PubMed] [Google Scholar]
  2. Kvols L. K., Moertel C. G., O'Connell M. J., Schutt A. J., Rubin J., Hahn R. G. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986 Sep 11;315(11):663–666. doi: 10.1056/NEJM198609113151102. [DOI] [PubMed] [Google Scholar]
  3. Reichlin S. Somatostatin. N Engl J Med. 1983 Dec 15;309(24):1495–1501. doi: 10.1056/NEJM198312153092406. [DOI] [PubMed] [Google Scholar]
  4. Reubi J. C., Cortès R., Maurer R., Probst A., Palacios J. M. Distribution of somatostatin receptors in the human brain: an autoradiographic study. Neuroscience. 1986 Jun;18(2):329–346. doi: 10.1016/0306-4522(86)90158-2. [DOI] [PubMed] [Google Scholar]
  5. Reubi J. C., Heitz P. U., Gyr K. Vasoactive intestinal peptide producing tumour contains high density of somatostatin receptors. Lancet. 1987 Mar 28;1(8535):741–742. doi: 10.1016/s0140-6736(87)90375-8. [DOI] [PubMed] [Google Scholar]
  6. Reubi J. C., Horisberger U., Essed C. E., Jeekel J., Klijn J. G., Lamberts S. W. Absence of somatostatin receptors in human exocrine pancreatic adenocarcinomas. Gastroenterology. 1988 Sep;95(3):760–763. doi: 10.1016/s0016-5085(88)80025-8. [DOI] [PubMed] [Google Scholar]
  7. Reubi J. C., Horisberger U., Lang W., Koper J. W., Braakman R., Lamberts S. W. Coincidence of EGF receptors and somatostatin receptors in meningiomas but inverse, differentiation-dependent relationship in glial tumors. Am J Pathol. 1989 Feb;134(2):337–344. [PMC free article] [PubMed] [Google Scholar]
  8. Reubi J. C., Häcki W. H., Lamberts S. W. Hormone-producing gastrointestinal tumors contain a high density of somatostatin receptors. J Clin Endocrinol Metab. 1987 Dec;65(6):1127–1134. doi: 10.1210/jcem-65-6-1127. [DOI] [PubMed] [Google Scholar]
  9. Reubi J. C., Kvols L. K., Waser B., Nagorney D. M., Heitz P. U., Charboneau J. W., Reading C. C., Moertel C. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res. 1990 Sep 15;50(18):5969–5977. [PubMed] [Google Scholar]
  10. Reubi J. C., Landolt A. M. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. J Clin Endocrinol Metab. 1989 Apr;68(4):844–850. doi: 10.1210/jcem-68-4-844. [DOI] [PubMed] [Google Scholar]
  11. Reubi J. C., Lang W., Maurer R., Koper J. W., Lamberts S. W. Distribution and biochemical characterization of somatostatin receptors in tumors of the human central nervous system. Cancer Res. 1987 Nov 1;47(21):5758–5764. [PubMed] [Google Scholar]
  12. Reubi J. C., Maurer R., von Werder K., Torhorst J., Klijn J. G., Lamberts S. W. Somatostatin receptors in human endocrine tumors. Cancer Res. 1987 Jan 15;47(2):551–558. [PubMed] [Google Scholar]
  13. Reubi J. C. Somatostatin receptors as markers for endocrine tumors. JAMA. 1987 Jun 19;257(23):3277–3277. [PubMed] [Google Scholar]
  14. Reubi J. C., Torhorst J. The relationship between somatostatin, epidermal growth factor, and steroid hormone receptors in breast cancer. Cancer. 1989 Sep 15;64(6):1254–1260. doi: 10.1002/1097-0142(19890915)64:6<1254::aid-cncr2820640615>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  15. Schonbrunn A. Glucocorticoids down-regulate somatostatin receptors on pituitary cells in culture. Endocrinology. 1982 Apr;110(4):1147–1154. doi: 10.1210/endo-110-4-1147. [DOI] [PubMed] [Google Scholar]
  16. Viguerie N., Estève J. P., Susini C., Logsdon C. D., Vaysse N., Ribet A. Dexamethasone effects on somatostatin receptors in pancreatic acinar AR4-2J cells. Biochem Biophys Res Commun. 1987 Sep 30;147(3):942–948. doi: 10.1016/s0006-291x(87)80161-4. [DOI] [PubMed] [Google Scholar]

Articles from The Yale Journal of Biology and Medicine are provided here courtesy of Yale Journal of Biology and Medicine

RESOURCES